Europe
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
Shares of Mesoblast Limited are down more than 30% in premarket trading following the company’s disappointing announcement late Thursday regarding its stem-cell therapy trial in ventilator-dependent patients with COVID-19 patients who have moderate to severe acute respiratory distress syndrome.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Despite some setbacks, the company anticipates its vaccine could be available for use in the United Kingdom within the next several weeks.
Novartis is acquiring Cambridge, Massachusetts-based Cadent Therapeutics for $210 million up front and a possible $560 million in milestone payments.
The company is significantly expanding its footprint with new facilities in the United States and in Europe.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Novartis’ Entresto is well on its way to receiving approval as a treatment for heart failure patients following overwhelming support from a U.S. Food and Drug Administration (FDA) advisory committee.
It’s been a busy day so far for biopharma news and updates. Read on for more.
PRESS RELEASES